Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aptevo Therapeutics (APVO) Shares Outstanding (2016 - 2025)

Aptevo Therapeutics' Shares Outstanding history spans 10 years, with the latest figure at $8.3 million for Q3 2025.

  • For Q3 2025, Shares Outstanding rose 35927.43% year-over-year to $8.3 million; the TTM value through Sep 2025 reached $8.3 million, up 35927.43%, while the annual FY2024 figure was $72922.0, 12114.74% up from the prior year.
  • Shares Outstanding for Q3 2025 was $8.3 million at Aptevo Therapeutics, up from $3.2 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $14.5 million in Q3 2023 and bottomed at $597.0 in Q4 2023.
  • The 5-year median for Shares Outstanding is $3.2 million (2025), against an average of $3.2 million.
  • The largest annual shift saw Shares Outstanding tumbled 99.92% in 2022 before it soared 35927.43% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $4.9 million in 2021, then crashed by 99.92% to $3971.0 in 2022, then plummeted by 84.97% to $597.0 in 2023, then soared by 12114.74% to $72922.0 in 2024, then skyrocketed by 11282.02% to $8.3 million in 2025.
  • Per Business Quant, the three most recent readings for APVO's Shares Outstanding are $8.3 million (Q3 2025), $3.2 million (Q2 2025), and $72925.0 (Q1 2025).